Newsroom | 4818 results

NEW YORK--(BUSINESS WIRE)--Wisp, the largest pure play women's telehealth company in the U.S., today announced the expansion of its weight care vertical, delivering the most affordable all-in, name-brand GLP-1s directly to the doors of its over 1.5 million patients. Patients can now access safe and effective weight loss treatments with savings up to 50 percent, no insurance required — an offering that’s not currently available through any other provider in the country. One in eight adults have...

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care® (NASDAQ: TNDM), a global insulin delivery and diabetes technology company, today announced the publication of a study, "Adults with Type 2 Diabetes Benefit from Automated Insulin Delivery Irrespective of C-peptide Level," in the American Diabetes Association’s Diabetes Care. The study, a sub-analysis from the 2IQP randomized, controlled trial, found that the Control-IQ+ automated insulin delivery (AID) system was beneficial for adults with insul...

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (“Insulet” or the “Company”), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that Flavia Pease will succeed Ana Maria Chadwick as Executive Vice President, Chief Financial Officer, effective September 30, 2025. Ms. Chadwick will become a Senior Advisor to Insulet to ensure a smooth transition. “I want to personally thank Ana, who has provided steady and thoughtful leader...

CHAPEL HILL, N.C. & TORONTO & LONDON & ZUG, Switzerland--(BUSINESS WIRE)--AESARA, a leading digital-forward Value & Access agency, today announced the appointment of Anita Brogan, PhD, as Vice President, Value & Evidence - Modeling and Communications within its Value and Evidence team. With over 20 years of experience designing and building economic analyses to support value assessment and patient access for innovative healthcare interventions, Anita brings deep expertise in both global...

VIENNA--(BUSINESS WIRE)--DexCom, Inc. (Nasdaq: DXCM), a global leader in glucose biosensing, will present new product features and a compilation of new evidence that shows the benefits of its glucose biosensing technology for people with all types of diabetes at the upcoming 61st annual European Association for the Study of Diabetes (EASD) Conference. “Each year, EASD provides a high-profile opportunity to highlight our latest product innovations and new clinical data that demonstrates how Dexc...

NEWTON, Mass.--(BUSINESS WIRE)--Inflammasome Therapeutics (https://www.inflam.com), is a clinical-stage biotech company developing a new class of inflammasome inhibitors called Kamuvudines for ophthalmic and neurological conditions. Today, the company announced that the first of these drugs, K8, delivered via a sustained release intraocular implant for the treatment of Geographic Atrophy (GA), reduced GA lesion area growth by more than 50% following three months of treatment among an initial co...

IRVINE, Calif.--(BUSINESS WIRE)--Diality Inc., a medical device company that has developed the Moda-flx™ Hemodialysis System, today announced the first patient treatment in its PRESCRIBE Diality Home Hemodialysis Clinical Trial in partnership with aQua Research Institute and aQua Dialysis in Houston, Texas. Diality is conducting the PRESCRIBE Diality trial under an Investigational Device Exemption (IDE) to evaluate a home use indication for the Moda-flx Hemodialysis System. The Moda-flx Hemodia...

SAN DIEGO & BURNABY, British Columbia--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today the launch of its first open call in the U.S. and Canada in search of the next diabetes advocates. Those selected will experience a once-in-a-lifetime opportunity to raise awareness and share their voice on a global scale this World Diabetes Day (Nov. 14) and beyond. Now through Sept. 19, people from 2 years and older living with all types of diabetes and...

LOS ANGELES--(BUSINESS WIRE)--City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the U.S., launched an innovative national clinical trials model to expand access to emerging life-saving cancer treatments to more patients across the country. This model simplifies the opening of new trial locations and streamlines patient enrollment with the goal of accelerating the development of new cancer treatments and improving clinical care. As the first acade...

ROCHESTER, Minn.--(BUSINESS WIRE)--RION, a clinical-stage regenerative medicine company and global leader in exosome-based therapeutics, today announced the formation of INTENT Biologics, a new independent biotechnology company focused exclusively on developing first-in-class exosome therapies for Inflammation & Immunology (I&I). INTENT Biologics launches with exclusive, perpetual worldwide rights to RION’s Purified Exosome Product (PEP™) biologic platform in I&I and will advance PE...